Adaptive RadioTherapy for OroPharynx Cancer
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · May 24, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treating oropharynx cancer, specifically looking at how using MRI (a type of imaging) during treatment can help reduce swallowing problems, also known as dysphagia. Researchers are comparing two groups of patients: one that receives standard treatment and another that has their radiation therapy adjusted based on MRI results during treatment. The goal is to find out if the MRI-guided approach leads to fewer swallowing issues six months after treatment.
To participate, individuals must be at least 18 years old and have a confirmed diagnosis of squamous cell carcinoma of the oropharynx at an advanced stage (T3-T4). They should be planning to receive curative treatment with radiation, possibly along with chemotherapy. Some patients who have received prior chemotherapy but still have cancer present may also qualify. Participants can expect regular assessments and follow-ups to evaluate their swallowing ability and overall health during and after treatment. This study is currently recruiting participants and aims to improve the quality of life for those undergoing treatment for this type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Ability to provide written informed consent.
- • Stage T3-T4N0-3 as per AJCC 8th edition
- • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- • Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
- • Planned for curative radiotherapy +/- chemotherapy
- • For females of child-bearing age, a negative pregnancy test
- • Patients treated with induction chemotherapy can be included if they have residual tumor in place.
- Exclusion Criteria:
- • Previous irradiation of the head and neck (HNC) region, excluding superficial radiation therapy for non-melanomatous skin cancer
- • Previous surgery of the HNC region (except for incisional or excisional biopsies)
- • Pregnancy or breastfeeding
- • Connective tissue disease
- • Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
- • Patients with contra-indications to MRI will be excluded.
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, , Australia
Montréal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials